Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Blood (2024) 144 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2024-210731

Published: 2024

Journal Articles

Association of Hypometilating Agents + Venetoclax in the Treatment of Secondary Acute Myeloid Leukemias Evolved from Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 6711.

https://doi.org/10.1182/blood-2024-207060

Published: 2024

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML

Matteo Marchesini, Andrea Gherli, Elisa Simoncini, Anna Montanaro, Natthakan Thongon, Luca Pagliaro, Federica Vento, Lucas Moron Dalla Tor, Chiara Liverani, Raffaella Zamponi, Elena Follini, Benedetta Cambò, Bruno Lorusso, Roberta La Starza, Antonio Cuneo, Cristina Mecucci, Simona Colla, Federico Quaini, Giovanni Roti

Blood (2022) 140 (Supplement 1): 673–674.

https://doi.org/10.1182/blood-2022-158990

Published: 2022

Journal Articles

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-139981

Published: 2020

Journal Articles

Higher Monocyte Chemoattractant Protein-1 Levels in Myelofibrosis Are Sustained By the rs1024611 Single Nucleotide Polymorphism and Correlate with Disease Subtype and Severity

Elena Masselli, MD, Giulia Pozzi, MS, Cecilia Carubbi, PhD, Luca Pagliaro, MD, Elena Follini, MD, Benedetta Cambò, MD, Monica Crugnola, MD, Giuliana Gobbi, PhD, Prisco Mirandola, PhD, Franco Aversa, MD, Marco Vitale, MD

Blood (2018) 132 (Supplement 1): 1785.

https://doi.org/10.1182/blood-2018-99-111719

Published: 2018

Journal Articles

Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies

Blood (2018) 132 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2018-99-116881

Published: 2018

Journal Articles

The -2518A/G (rs1026411) Regulatory Region Polymorphism of the Monocyte Chemoattractant Protein-1 (MCP-1) Is Associated with Secondary Myelofibrosis

Elena Masselli, MD, Cecilia Carubbi, PhD, Benedetta Cambò, MD, Giulia Pozzi, MS, Giuliana Gobbi, PhD, Prisco Mirandola, PhD, Elena Follini, MD, Luca Pagliaro, MD, Francesco Bonatti, PhD, Antonio Percesepe, MD PhD, Franco Aversa, MD, Marco Vitale, MD

Blood (2017) 130 (Supplement 1): 5286.

https://doi.org/10.1182/blood.V130.Suppl_1.5286.5286

Published: 2017

Journal Articles

Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML

Federico Quaini, MD PhD, Rodanthi Fioretzaki, MD, Monica Crugnola, MD, Angela Falco, PhD, Denise Madeddu, PhD, Luisa Craviotto, MD, Benedetta Cambò, MD, Lucia Prezioso, MD PhD, Gabriella Sammarelli, PhD, Giannalisa Todaro, PhD, Gallia Graiani, PhD, Cristina Mancini, MD, Eugenia Martella, MD, Francesca Re, MD, Nicola Giuliani, MD, PhD, Franco Aversa, MD

Blood (2016) 128 (22): 4302.

https://doi.org/10.1182/blood.V128.22.4302.4302

Published: 2016

Journal Articles

Therapeutic Strategy for Elderly Patients with ACUTE Myeloid Leukemia (AML) Carrying the DNMT3A Mutation

Elena Rossetti, MD, Monica Crugnola, MD, Cecilia Caramatti, MD, Luisa Craviotto, MD, Elena Masselli, MD, Lucia Prezioso, MD PhD, Alessandro Monti, MD, Benedetta Cambò, MD, Chiara Lambertini, MD, Claudio Pietropaolo, Anna Minardi, Gabriella Sammarelli, PhD, Sabrina Bonomini, Rodanthi Fioretzaki, MD, Franco Aversa, MD

Blood (2014) 124 (21): 5269.

https://doi.org/10.1182/blood.V124.21.5269.5269

Published: 2014

Journal Articles

Protein Kinase C Epsilon Inhibition Restores In-Vitro Megakaryocyte Differentiation Of Primary Myelofibrosis Hematopoietic Progenitors

Elena Masselli, MD, Prisco Mirandola, PhD, Giuliana Gobbi, PhD, Cecilia Carubbi, MS, Sabrina Bonomini, PhD, Monica Crugnola, MD, Filomena Russo, MD, Luisa Craviotto, MD, Benedetta Cambò, MD, Caterina Plenteda, MD, Elena Rossetti, MD, Cecilia Caramatti, MD, Franco Aversa, MD, Marco Vitale, MD

Blood (2013) 122 (21): 114.

https://doi.org/10.1182/blood.V122.21.114.114

Published: 2013

NARROW

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Association of Hypometilating Agents + Venetoclax in the Treatment of Secondary Acute Myeloid Leukemias Evolved from Chronic Myelomonocytic Leukemia

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Higher Monocyte Chemoattractant Protein-1 Levels in Myelofibrosis Are Sustained By the rs1024611 Single Nucleotide Polymorphism and Correlate with Disease Subtype and Severity

Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies

The -2518A/G (rs1026411) Regulatory Region Polymorphism of the Monocyte Chemoattractant Protein-1 (MCP-1) Is Associated with Secondary Myelofibrosis

Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML

Therapeutic Strategy for Elderly Patients with ACUTE Myeloid Leukemia (AML) Carrying the DNMT3A Mutation

Protein Kinase C Epsilon Inhibition Restores In-Vitro Megakaryocyte Differentiation Of Primary Myelofibrosis Hematopoietic Progenitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only